A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

Clinical trial NCT06343805 · RECRUITING

Trial details

NCT number: NCT06343805
Sponsor: Ajax Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Primary Myelofibrosis Post-Essential Thrombocythemia Myelofibrosis Post-Polycythemia Vera Myelofibrosis PMF PPV-MF PET-MF

Start date: 2024-10-23
Primary completion: 2026-10-15
Enrollment: 76

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.